- Home
- GNLN vs BCAB Comparison
GNLN vs BCAB Comparison
Compare GNLN & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLN | BCAB |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.5M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNLN | BCAB |
|---|---|---|
| Price | $0.87 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 247.5K | ★ 1.7M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,275,000.00 | $300,000.00 |
| Revenue This Year | $1,541.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.01 | $0.13 |
| 52 Week High | $7.73 | $1.43 |
Technical Indicators
Market Signals| Indicator | GNLN | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 38.20 |
| Support Level | $0.72 | $0.13 |
| Resistance Level | $1.80 | $0.27 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 98.74 | 11.09 |
Price Performance
Historical ComparisonAbout GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.